Session » T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 120

Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 110

Bioinformatics Analysis of Transcriptomics Data Reveals That SRSF1 Is a Novel Molecular Brake for the T Cell Activation Program and Controls Key Cytokine Signaling Genes Implicated in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 123

Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope

9:00AM-11:00AM: Abstract Number: 101

CD126 Negative CD4+Foxp3+ Cell Represents a Superior Treg Subset in Treating Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 115

CD8+ Cytotoxic T Lymphocytes Are Clonally-expanded in IgG4-related Disease and Home to Affected Tissues

9:00AM-11:00AM: Abstract Number: 96

Characterizing the Brain T Cell Receptor Repertoire in Neuropsychiatric Lupus

9:00AM-11:00AM: Abstract Number: 116

Defective EZH2 Expression Attenuates Treg Differentiation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 89

Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis

9:00AM-11:00AM: Abstract Number: 125

Elevated Proliferative Capacity of CD8+ T Cells in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 107

Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium

9:00AM-11:00AM: Abstract Number: 91

Histonedeacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 95

IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE

9:00AM-11:00AM: Abstract Number: 112

Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 113

In Vitro Characterization of the Effect of Cenerimod, a Potent and Selective Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulator, on S1P1 Receptor Expression, Receptor Internalization, and Migration of Primary Human T Cells in the Presence or Absence of Glucocorticoids

9:00AM-11:00AM: Abstract Number: 121

In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition

9:00AM-11:00AM: Abstract Number: 106

Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects

9:00AM-11:00AM: Abstract Number: 122

Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis

9:00AM-11:00AM: Abstract Number: 93

Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis

9:00AM-11:00AM: Abstract Number: 87

KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 97

Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 99

Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis

9:00AM-11:00AM: Abstract Number: 119

Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model

9:00AM-11:00AM: Abstract Number: 108

Mucosal Associated Invariant T Cells in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 92

Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls

9:00AM-11:00AM: Abstract Number: 104

Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders

9:00AM-11:00AM: Abstract Number: 114

Persistent Synovial Resident Memory T Cells Mediate Arthritis Flares

9:00AM-11:00AM: Abstract Number: 118

Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 98

Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 103

Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells

9:00AM-11:00AM: Abstract Number: 102

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)

9:00AM-11:00AM: Abstract Number: 90

SLAMF6 Clustering Is Required to Augment Autoimmune T Cell Activation

9:00AM-11:00AM: Abstract Number: 109

Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis

9:00AM-11:00AM: Abstract Number: 100

Targeting ITK Signaling Ameliorates Collagen-Induced Arthritis via Shifting the Balance Between Th17 and Regulatory Th17 Cells

9:00AM-11:00AM: Abstract Number: 105

The DLEU2/miR-15a/16-1 Cluster Inhibit Foxp3+ Treg Cells in Salivary Glands of pSS via Targeting Foxp3

9:00AM-11:00AM: Abstract Number: 117

The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 111

The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles

9:00AM-11:00AM: Abstract Number: 86

THOR-809: An IL-2 Engineered from an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders

9:00AM-11:00AM: Abstract Number: 124

Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 94

Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells

9:00AM-11:00AM: Abstract Number: 88

Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].